Evidence map›Paper›PMID 35032367›Full record

ArticleCancer communications (London, England)2022

Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials.

Sung Hwan Lee, Yun Seong Jeong, Sunyoung Lee, Bo Hwa Sohn, Ho Kyoung Hwang, Gi Hong Choi, Chang Moo Kang, Jin Sub Choi, Woo Jung Lee, Jae-Ho Cheong and 6 more

Abstract readLetter
In one paragraph

Article in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sung Hwan LeeDepartment of Systems Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yun Seong JeongDepartment of Systems Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sunyoung LeeDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Bo Hwa SohnDepartment of Systems Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ho Kyoung HwangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Gi Hong ChoiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Chang Moo KangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Jin Sub ChoiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Woo Jung LeeDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Jae-Ho CheongDepartment of Surgery, Yonsei University Health System, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Hee Jin JangDivision of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, 77030, USA.
Ahmed KasebDepartment of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Lewis RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55902, USA.
Sun Young YimDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Yun Shin ChunDepartment of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ju-Seog LeeDepartment of Systems Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular CarcinomaP50CA217674 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERETTA, LAURA, KASEB, AHMED · 2019 to 2023
$11.3M
Regulation of the Tumor Microenvironment in Hepatocellular CarcinomaR01CA165076 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO, ROBERTS, LEWIS R · 2012 to 2016
$2.0M
PEA15 IN DEVELOPMENT OF LIVER CANCER AND ITS THERAPEUTIC IMPLICATIONR01CA237327 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LEE, JU-SEOG · 2020 to 2024
$1.8M
NCI NIH HHS N01 CA015083NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA210964NCI NIH HHS P50 CA217674NCI NIH HHS R01 CA165076NCI NIH HHS R01 CA237327
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularLiver NeoplasmsBile Ducts, IntrahepaticHumansStem Cells

Identifiers

PMID35032367
PMCPMC8822477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.